Why Satellos Bioscience Inc.’s (MSLE) Stock Is Up 5.95%
As of Monday, August 31, Satellos Bioscience Inc.’s MSLE share price has surged by 5.95%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Commentary & Analysis
Why Satellos Bioscience Inc.’s (MSLE) Stock Is Up 6.58%
As of Monday, August 31, Satellos Bioscience Inc.’s MSLE share price has surged by 6.58%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Satellos Bioscience Inc.’s (MSLE) Stock Is Up 7.24%
As of Wednesday, August 19, Satellos Bioscience Inc.’s MSLE share price has surged by 7.24%, which has investors questioning if this is right time to sell.Michael Rose
Why Satellos Bioscience Inc.’s (MSLE) Stock Is Down 5.75%
As of Friday, July 31, Satellos Bioscience Inc.’s MSLE share price has dipped by 5.75%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Satellos Bioscience Inc.’s (MSLE) Stock Is Down 6.03%
As of Monday, July 20, Satellos Bioscience Inc.’s MSLE share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | MSLE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $201.3 | $272.4 | 27% |
|
| Shares Out (Mil) | 20.8 | 54.6 | 31% |
|
| Institutional Ownership | 85.7% | 92.9% | 54% |
|
| Float (Mil) | 18.0 | 42.3 | 27% |
|
| Beta | 1.17 | 0.94 | 69% |
|
| Avg Daily Volume (000s) | 36 | 526 | 25% |
|
| Price Change (52-week) |
58.2% | 54.9% | 85% |
|
| Growth | MSLE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (83.4%) | (10.1%) | 2% |
|
| EPS (5yr) | (15.3%) | 15.4% | 18 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (62.7%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.618) | ($2.358) | ($2.728) | |
| Month Ago EPS | ($0.623) | ($2.403) | ($1.338) | |
| # Rev Up | 1 | 1 | na | |
| # Rev Down | 1 | 1 | na | |
| Three Months Ago EPS | ($0.730) | ($2.640) | ($2.840) | |
| Year/Year Chg | 9.8% | 38.4% | 65.5% | |
| Financials | MSLE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($35) | ($43) | 19% |
|
| EPS (TTM) | ($1.990) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($31) | $2 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $151 | $182 | 24% |
|
| Valuation | MSLE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.37 | 2.62 | 69% |
|
| P/E | na | 19.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MSLE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.0% | na |
|
| Net Margin | na | (73.0%) | na |
|
| ROA | (64.8%) | (47.7%) | 9% |
|
| ROE | (70.4%) | (55.0%) | 12% |
|
| Liabilities to Assets | 8.9% | 29.3% | 5% |
|
| F-Score | 2 | 2 | 7% |
|
Satellos Bioscience Inc. did not pass any screens on 9/17/2026.
